| |
Technology Platform Highlights
- The Standard of Care for patients with reduced or missing critical hormones or proteins such as insulin is often monitoring and injecting these proteins multiple times a day with a consequence of poor compliance and serious side effects resulting in $150B/yr hospital costs for diabetes alone. Cell therapy is a new and increasing alternative for patients with severe disease; however, there is no currently approved device to house and protect these cells in the body. Instead, often cells are injected into vessels in an extremely expensive ($100,000) and risky procedure, where most die through blood-derived inflammation and clotting, resulting in the need for reoperations. Hence cell therapy is limited by expensive procedures, poor cell survival and inappropriate delivery as well as lack of available donors.
- Sernova's Cell Pouch System™ is a versatile, scalable, matchbook-sized, multi-chambered polymer device made of FDA approved materials, designed by biomedical engineers and biologists. Placed under the skin in a simple inexpensive procedure, it develops organ-like characteristics for delivery and natural housing of therapeutic cells. A natural environment is expected to conserve cell number, and promote natural function - increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.
- Sernova's Sertolin™ is for patients who have had therapeutic cell therapy who want to avoid toxic and expensive anti-rejection drugs ($10-15,000/yr). Sertolin(tm) is a patented cellular technology which when combined with therapeutic cells protects them from attack by the immune system. In fact animal models have shown that the combination of these protector and therapeutic cells leads to long-term functional survival of the therapeutic cells without drug therapy.
| |
